Lung Cancer

From the lung cancer death of “Seinfeld” actress Kathryn Kates to a patient with cancer who broke a rowing world record, here’s what’s happening in the cancer landscape this week.

An expert oncologist details the design, outcomes, and clinical implications of the IMpower010 trial.

Dr. Jessica Donington explains how the results of the ADAURA trial changed the treatment algorithm in the adjuvant setting in early non-small cell lung cancer.

Researchers plan to enroll 60 patients in the first-in-human phase 1 clinical trial to assess the safety and preliminary clinical activity of an anti-CD39 monoclonal antibody to treat advanced solid tumors.

After promising phase 3 clinical trial results, the FDA will consider Libtayo for approval to treat patients with advanced non-small cell lung cancer, regardless of PD-L1 status.

A new study to evaluate the accuracy of a blood test for detecting lung cancer in high-risk adults has enrolled its first participant with plans to enroll thousands more.

Martin Dietrich, MD, PhD, describes the toxicity profiles of chemotherapy agents used in the adjuvant setting in early non-small cell lung cancer.

Two experts detail the use of adjuvant therapy, including chemotherapy, in treating early non-small cell lung cancer.

While robotic navigational bronchoscopy is an exciting advancement in diagnosing and staging lung cancer, the procedure does come with some risks and factors to consider, explained one expert.

In an interim analysis from a phase 3 trial of Keytruda, the use of the immunotherapy drug was associated with significantly improved disease-free survival in patients with non-small cell lung cancer.

Dr. Martin Dietrich explains the role of molecular testing in early non-small cell lung cancer.

Martin Dietrich, MD, PhD, and Jessica Donington, MD, MSCR, provide an overview on early non-small cell lung cancer and the available treatment options.

Certain allergy medications like Zyrtec and Claritin may be the key for more patients to tolerate immunotherapy for several cancer types.

Angela Criswell, director of quality screening and program initiatives at GO2 Foundation for Lung Cancer, discusses early detection and screening for lung cancer.

Daniel Saez, treatment and trials navigator at the GO2 Foundation for Lung Cancer, discusses biomarker testing and precision medicine in lung cancer.

Susan Smedley, national manager of community fundraising and endurance events at GO2 Foundation for Lung Cancer, offers resources for patients with lung cancer and their loved ones, as well as ways to get involved in the community.

Susan Smedley, national manager of community fundraising and endurance events at GO2 Foundation for Lung Cancer, discusses quality of life in lung cancer, and ways patients can communicate preferences to their health care providers.

The Food and Drug Administration will offer guidance and expedited review to CLN-081, a novel drug that is promising for the treatment of EGFR exon 20-mutated non-small cell lung cancer.

An oncologist from Fox Chase Cancer Center in Philadelphia explains the early career mentorship that inspired his successful lung cancer career.

Not having known much about lung cancer, a woman describes her shock at receiving a diagnosis despite being a non-smoker.

A lung cancer doctor explains how he got lucky to fill in a role in the lung cancer space, and his career and passion took off from there.

A woman who has worked with Upal Basu Roy in the lung cancer space for many years explains why he is a lung cancer hero to everyone he has worked with, due to his dedication and empathy.

A lung cancer survivor describes a passionate advocate who has changed the world of many patients.

A man writes about how his wife’s doctor saved her life after she was given three weeks to three months to live.

The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.